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Abstract
Comorbidity is the occurrence of concomitant disease in addition to an index disease of interest or the simultaneous occurrence of 
multiple diseases in an individual. Lung cancer is associated with age and smoking, and both age and smoking are strongly asso-
ciated with comorbidity. Lung cancer is the most common malignancy in the world. Comorbidity, such as diseases of cardiovascu-
lar, pulmonary and other systems may influence prognosis in lung cancer as well as complicate its treatment. In this paper we 
tried to conclude the significance of the individual comorbidities in lung cancer and their impact on particular treatment method.
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Introduction
For many years, cancer patients have been 
staged by the size of their tumor while how sick 
they are because of the tumor and other medical 
conditions was neglected. The present system 
of cancer classification does not consider the 
important patient-based prognostic factors, such 
as the general health of the patient, defined as 
the number and pathophysiological severity of 
coexisting diseases, illnesses, or conditions [1]. 
These conditions and diseases, which exist be-
fore cancer diagnosis and are not adverse effects 
of cancer treatment, are generally referred to as 
comorbidities [2]. During a routine treatment 
selection process and clinical decision-making, 
comorbidity is generally not considered in the 
design of cancer data sets or included in observa-
tional research. In many cases, comorbid health 
problems are so severe that they impact directly 
on survival and prohibit the use of preferred 
antineoplastic therapies. Precise comorbidity 
information, along with patient demographics, 
behavioral risk characteristics, site of cancer, 
and morphologic stage of the tumor, is essential 
for comprehensive risk adjustment in cancer. 
Accurate risk adjustment is necessary for obser-
vational and health services research, including 
comparison of outcomes of different treatments 
and quality assessment [1−8].
Lung cancer is the most common malignancy 
in the world. It is one of the main causes of death 
among men between 50 and 70 years of age [9]. It 
is the most common cancer in men and second in 
women but according to mortality due to cancer it 
takes the first place in both sexes. On the basis of 
the histopathological classification, lung cancer is 
divided into two main groups: (1) small cell lung 
cancer (SCLC), representing about 20% of cases, 
and (2) non-small cell lung cancer (NSCLC), 
which consists of approximately 75% of all lung 
tumor diagnoses. Histologically, NSCLC is divid-
ed into the following subtypes — squamous cell 
carcinoma of lung (SCC), adenocarcinoma (AC) 
and large cell carcinoma (LCC) [10]. Comorbidity, 
such as diseases of the cardiovascular, pulmonary, 
and other systems may influence prognosis in lung 
cancer as well as complicate its treatment [11]. 
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The aim of this review is to comprehensively 
narrate the comorbid conditions that often co-
exist with lung cancer, along with their reported 
prevalence and their significant impacts in the 
disease survival and management. 
Lung cancer comorbidities and survival influence
Cancer survival mainly depends on patient 
characteristics, the histology and pathology of the 
tumor, stage at diagnosis, host-tumor interaction, 
and comorbidities. Comorbidity has an influ-
ence on each patient’s initial treatment and the 
treatment effectiveness of patient care. Previous 
studies have demonstrated that less aggressive 
treatment is given to patients with breast cancer, 
prostate cancer, lymphoma, or lung cancer who 
have specific existing comorbidities [12−17]. 
Several diseases such as hypertension, ischemic 
heart disease, cerebrovascular disease, chronic 
obstructive pulmonary disease (COPD), and 
diabetes mellitus (DM) are considered to have 
a significant influence on the survival of cancer 
patients and thus overall lung cancer population 
[11, 13, 18].
A major problem in comorbidity issues is also 
the co-existence of pulmonary diseases before 
the diagnosis of lung tumor, which may delay 
the diagnosis of lung cancer. The most common 
respiratory comorbidities which often delay lung 
cancer diagnosis, are shown in Figure 1 [modified 
on the basis of 19].
Estimating the risk of death for patients with 
lung cancer plays an important role in the choice 
of oncologic therapy. The Charlson Comorbidity 
Index (CCI, Comorbidity Adjusted Life Expectan-
cy) is a commonly used measure of comorbidity. 
CCI assess whether a patient will live long enough 
to benefit from a specific screening measure or 
medical intervention [20]. Apart from currently 
existing CCI system, current researches give 
information about new promising comorbidity 
evaluation systems in lung cancer patients — 
Simplified Comorbidity Score System (SCSS) 
(Table 1) and the modified Glasgow Prognostic 
Score (mGPS) [21−23]. 
Age
The presence of comorbidity in lung cancer 
patients increases with age. The increasing mean 
age of the population will therefore increase the 
number of patients diagnosed with one or more 
other serious diseases at the time of cancer diag-
nosis. Age occurs to be a strong negative prog-
nostic factor similar to tumor stage and patient 
performance status [24]. However according to 
resection status, Pei et al. [25] study results of the 
postoperative complications after lung resection 
for NSCLC in elderly patients are encouraging. 
Here pulmonary resection for NSCLC in patients 
Figure 1. Respiratory comorbidity prevalence associated with lung 
cancer. TB indicates tuberculosis; COPD, chronic obstructive pulmo-
nary disease [modified on the basis of 19]
Table 1. Simplified Comorbidity Score System (SCSS)
Score Condition
1 point Myocardial infarction (history, not ECG changes only)
Congestive heart failure
Peripheral disease (includes aortic aneurysm ≥ 6 cm)






Mild liver disease (without portal hypertension, inlcu-
des chronic hepatitis)
Diabetes without end-organ damage (excludes diet-
controlled alone)
2 points Hemiplegia
Moderate or severe renal disease
Diabetes with end-organ damage (retinopathy, neuro-
pathy,nephropathy, or brittle diabetes)
Tumor without metastasis (exclude if > 5 y from 
diagnosis)
Leukemia (acute or chronic)
Lymphoma
3 points Moderate or severe liver disease
6 points Metastatic solid tumor
AIDS (not just HIV positive)
For each decade > 40 years of age, a score of 1 is added to the above score; 
ECG — electrocardiogram; CVA — cerebrovascular accident; TIA — transient 
ischemic attack; AIDS — acquired immunodeficiency syndrome; HIV — human 
immunodeficiency virus
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older than 70 years showed acceptable morbid-
ity and mortality. According to systemic NSCLC 
treatment, age may limit chemotherapy use for 
elderly patients [26].
Chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease 
(COPD) is a major burden throughout the world. 
It is associated with a significantly increased inci-
dence of lung cancer and may influence treatment 
options and outcome thus these diseases share 
common risk factors, COPD is the most common 
lung cancer comorbidity. The frequency of these 
diseases co-existanse was 52% in Islam et al. 
[27] study which assessed almost 5,683 patients. 
Impaired lung function confirming COPD is an 
independent risk factor for lung cancer [28−31]. 
Oxidative stress and inflammation may be a key 
link between COPD and lung cancer develope-
ment. COPD negatively influences possibility of 
radical treatment delivery options. According to 
Iachina et al. [32] patients with NSCLC and COPD 
have a 20% excess mortality than patients without 
this comorbidity.
Co-existance of lung cancer and COPD does 
not rule out the possibility of surgery. A recent re-
view concerning surgical treatment of lung cancer 
patients with COPD suggests milder criteria for 
surgical resection with curative intent, because 
limited surgical resections or nonsurgical ther-
apeutic options might provide inferior survival 
compared with resection complications risk [31]. 
In these patients physiotherapy represents an 
important part of preoperative and postoperative 
treatment [33].
Cardiovascular diseases (CVDs)
Cardiovascular comorbidity includes hyper-
tension, coronary artery disease, peripheral vas-
cular disease, arrhythmia and abdominal aortic 
aneurysm. CVDs are one of the most common 
comorbidities in lung cancer with prevalence 
from 12,9% to 43% according to different studies 
[27, 34]. Both frequency of cardiovascular comor-
bidity and lung cancer increases with age, thus 
the influence of cardiovascular comorbidity in 
lung cancer patients on their short- or long-term 
prognosis remains controversial.
Some authors reported that cardiovascular 
diseases have a negative effect on survival and 
mortality. The death rate frequency is 30% higher 
compared to cancer patients without this comor-
bidity [32]. This comorbidity worsen the surgical 
outcome. In patients who undergo surgery for 
stages I and II NSCLC it is also unfavourable sur-
vival marker [35−37]. On the other hand, several 
authors reported that cardiac comorbidity is not 
a risk or has little risk for mortality and morbidity 
following surgery for primary NSCLC [38−41]. 
What is more, some of these studies claim that the 
preoperative cardiovascular comorbidities, which 
included hypertension, cerebrovascular disease 
and coronary arteries disease and affected 71% 
of patients, didn’t have impact on postoperative 
complications.
Cerebrovascular disorders
Cerebrovascular disorders belong to CVDs 
and as a comorbidity need particular attention, 
because their presence increase mortality rate to 
20% in NSCLC patients in comparison to those 
without this comorbidity [32]. It is very unfa-
vourable prognostic factor for elderly patients 
undergoing thoracosurgical operation due to 
lung cancer. According to Dominguez-Ventura 
[42] study, previous stroke history in patiens ≥ 
80 years of age, increased fourfold risk of death. 
Cerebrovascular diseases had also a negative 
prognostic effect for those with extensive-stage 
SCLC [43].
Diabetes
There are many data concerning diabetes 
impact on worse cancer prognosis [44−55]. The 
occurrence of diabetes in lung cancer patients 
was 15.7% in Islam et al. [27] study. According 
to lung cancer, in Iachina et al. [32] patients with 
NSCLC and diabetes had a 20 % excess mortality 
than patients without this comorbidity. Shieh 
et al. [56] study revealed also elevated risk of 
mortality in lung cancer diabetic patients which 
suggest they deserve greater attention while un-
dergoing cancer treatment .
 Worse prognosis in diabetes co-existance 
may be caused by biological mechanisms related 
to hyperglycemia, hyperinsulinemia and inflam-
mation which result in tumor cell proliferation 
and metastases [47−49, 55].
Other unfavourable factors, due to diabetes- 
-related comorbidity, include less aggressive can-
cer treatment [57], poorer response to cancer treat-
ment [51–55], presentation with later-stage cancer 
due to suboptimal cancer screening practices and 
other preventive health-seeking behavior [58]. 
It is worth mentioning that there is some 
promising information about diabetes metformin 
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Table 2. Risk factors in lung cancer which affect surgical outcome
Risk factors References
Higher postoperative complication risk Lower postoperative complication risk
Charlson Comorbidity Index (CCI) scores ≥ 3
Pneumonectomy
Prolonged surgery
Thoracoscopic minimally invasive surgery [73]
Advanced age (≥ 70 years old) patients [74]
Advanced age (≥ 75 years old) [75]
Congestive heart failure Cerebrovascular disease
Renal disease 
[76]
treatment and lung cancer survival [59−62]. Ac-
cording to these studies metformin is associated 
with improved survival among diabetic patients 
with NSCLC, suggesting a potential anticancer 
effect of this drug.
Comorbidities and treatment influence
Lung cancer comorbidity and surgical 
treatment
In general, the decision for lung cancer sur-
gery should not be determined by patients’ age. 
According to a US large-scale study based on pa-
tients survival, outcomes for the subgroup aged 70– 
–79 years are similar to those of the subgroup aged 
80 years and older when patients receive single-mo-
dality local therapy [63]. There are some research-
ers assessing complication rates and risk factors 
in octogenarian lung cancer patients [42, 64−66]. 
Aoki et al. [65] investigated 35 patients aged 
80 years and over who underwent pulmonary 
resection, and demonstrated an operative mor-
tality rate of 0% and a morbidity of 60%. Port et 
al. [66] reported a perioperative mortality rate 
of 1.6% and a morbidity of 38% in the same age 
group. Dominguez-Ventura et al. [42] showed 
that mortality occurs in 6.3%, and postoperative 
complications occur in 48% of octogenarian lung 
cancer patients, with the risk factors of male gen-
der, symptomatic lung cancer with haemoptysis 
and previous stroke.
All above mentioned studies emphasise pa-
tient performance status (PS) as a major factor 
in lung cancer surgery safety. Exercise tolerance, 
as assessed by a symptom-limited stair-climbing 
test, predicts long-term lung cancer prognosis 
after surgery [67], postoperative early morbidity 
and death [68]. Some authors revealed that preop-
erative exercise training is beneficial in improving 
cardiorespiratory fitness in patients undergoing 
pulmonary resection [69]. This training should 
be encouraged in order to obtain better surgical 
outcomes and cancer-survival rates.
Although surgery offers the best chance of 
a cure for early stage NSCLC, postoperative 
morbidity and mortality, continue to be a major 
concern for thoracic surgeons after surgical resec-
tion of NSCLC. Improving the surgical outcome 
requires knowledge of the risk factors prior to 
surgery and that of postoperative mortality and 
morbidity. Preoperative comorbidities are reported 
to be associated not only with postoperative com-
plications [35, 40, 70, 71] but also with increased 
incidence of extended length of stay after NSCLC 
resection [72]. Particular risk factors in lung cancer 
which affects surgical outcome presents Table 2.
Lung cancer comorbidity and 
chemiotherapy
Patients with advanced lung malignancies 
often require cardiotoxic treatments. Increasing 
severity of co-existing comorbidity may increase 
the toxicity of specific treatments and may suffi-
ciently shorten remaining life expectancy to cancel 
therapy profits. It is also possible that the negative 
prognostic impact of severe comorbidity is actually 
due to the use of aggressive therapy. Due to that, 
patients with multiple medical comorbidities, of-
ten in decompensation, do not receive appropriate 
therapy. This cessation make difficult to recognize 
whether the decrease in survival is due to the co-
morbidity or less aggressive treatment.
The comorbidities impact on the systemic 
anticancer treatment is poorly assessed. On this 
issue there are no good data with a high level 
of evidence and literature is often limited to ex-
perts’ opinion and to case reports [77]. In spite 
of this there are some studies which provide 
data concerning inoperable patients. It is proved 
that chemotherapy and chemoradiation declined 
with increasing comorbidity and in particular 
increasing age [24].
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In Aarats et al. [43] study older patients with 
L-SCLC were less likely to be treated with CRT 
(chemoradiotherapy), intensive chemotherapy, 
and PCI (prophylactic cranial irradiation). Treat-
ment response and survival rates were lower with 
advancing age, but this may be attributed to poor 
performance status and suboptimal treatment 
rather than age. 
Conclusions
in conclusion, comorbidities are frequent 
in patients with lung cancer and have a great 
impact on their survival. Obtaining lung cancer 
comorbidity impact information is difficult as this 
particular cancer has one of the worst survival 
outcomes, thus is prognostically less informa-
tive [78]. It is impossible to omit comorbidity 
evaluation in choosing appropriate anticancer 
therapy. Because comorbidities impact on anti-
cancer treatment is still poorly assessed, there 
is a strong need for improving our knowledge in 
that field. Comorbidity information can be added 
to staging systems or incorporated into decision 
making programs to aid in patient consultation, 
improve patient decision making and match more 
individual therapy.
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